Benefits of Bayesian Dose Escalation Designs for Oncology Studies

As acceptance of flexible trial designs continues to advance, many sponsors are increasingly exploring alternate methods of dose escalation to support identification of a maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in open-label early phase or First-in-Human studies. Bayesian dose escalation designs have also coincided with advances in oncology therapy development, such as immunotherapies and antibody drug conjugates. These flexible methods may be more appropriate than those initially designed for chemotherapy drug development. In this webinar, the featured speaker will discuss and cover: Common types of open-label adaptive dose escalation designs Comparisons with rule-based designs How to apply and use these designs in oncology therapy development How to determine which design is best suited for a clinical trial Register to learn the benefits of Bayesian dose escalation designs for oncology therapy development.